{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T17:51:25Z","timestamp":1792950685130,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T00:00:00Z","timestamp":1778976000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":61,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-73166-1","type":"journal-article","created":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T01:03:30Z","timestamp":1778979810000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pharmabiotics, Phocaeicola dorei, ameliorates cholestatic liver fibrosis by alleviating macrophage efferocytosis of neutrophils"],"prefix":"10.1038","volume":"17","author":[{"given":"Jung A","family":"Eom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In Gyu","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Ye","family":"Hyun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7922-4634","authenticated-orcid":false,"given":"Na Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goo Hyun","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Jun","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Min","family":"Won","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Lim","family":"Ham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyeong Jin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Hak","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Hoon","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Joon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Tae","family":"Suk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,17]]},"reference":[{"key":"73166_CR1","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.3350\/cmh.2024.0506","volume":"30","author":"MN Kim","year":"2024","unstructured":"Kim, M. N. et al. KASL clinical practice guidelines for noninvasive tests to assess liver fibrosis in chronic liver disease. Clin. Mol. Hepatol. 30, S5\u2013S105 (2024).","journal-title":"Clin. Mol. Hepatol."},{"key":"73166_CR2","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1159\/000445269","volume":"34","author":"Y Koyama","year":"2016","unstructured":"Koyama, Y., Xu, J., Liu, X. & Brenner, D. A. New developments on the treatment of liver fibrosis. Dig. Dis. 34, 589\u2013596 (2016).","journal-title":"Dig. Dis."},{"key":"73166_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.730176","volume":"9","author":"Z Tan","year":"2021","unstructured":"Tan, Z. et al. Liver fibrosis: therapeutic targets and advances in drug therapy. Front. Cell Dev. Biol. 9, 730176 (2021).","journal-title":"Front. Cell Dev. Biol."},{"key":"73166_CR4","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1080\/1040841X.2025.2501590","volume":"51","author":"SJ Yoon","year":"2025","unstructured":"Yoon, S. J. et al. The crosstalk between gut microbiota and microbiota-derived metabolites in hepatocellular carcinoma. Crit. Rev. Microbiol. 51, 1315\u20131329 (2025).","journal-title":"Crit. Rev. Microbiol."},{"key":"73166_CR5","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1136\/gutjnl-2016-312729","volume":"65","author":"H Tilg","year":"2016","unstructured":"Tilg, H., Cani, P. D. & Mayer, E. A. Gut microbiome and liver diseases. Gut 65, 2035\u20132044 (2016).","journal-title":"Gut"},{"key":"73166_CR6","doi-asserted-by":"publisher","first-page":"e235","DOI":"10.3350\/cmh.2024.1150","volume":"31","author":"D Kim","year":"2025","unstructured":"Kim, D., Loomba, R. & Ahmed, A. Current burden of MASLD, MetALD, and hepatic fibrosis among US adults with prediabetes and diabetes, 2017-2023. Clin. Mol. Hepatol. 31, e235\u2013e238 (2025).","journal-title":"Clin. Mol. Hepatol."},{"key":"73166_CR7","doi-asserted-by":"publisher","first-page":"845","DOI":"10.3350\/cmh.2024.0349","volume":"30","author":"SP Sharma","year":"2024","unstructured":"Sharma, S. P. et al. Gut microbiome and metabolome signatures in liver cirrhosis-related complications. Clin. Mol. Hepatol. 30, 845\u2013862 (2024).","journal-title":"Clin. Mol. Hepatol."},{"key":"73166_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.trsl.2019.02.005","volume":"209","author":"R Zhou","year":"2019","unstructured":"Zhou, R., Fan, X. & Schnabl, B. Role of the intestinal microbiome in liver fibrosis development and new treatment strategies. Transl. Res. 209, 22\u201338 (2019).","journal-title":"Transl. Res."},{"key":"73166_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.634","volume":"11","author":"JS Yu","year":"2021","unstructured":"Yu, J. S. et al. Lactobacillus lactis and Pediococcus pentosaceus-driven reprogramming of gut microbiome and metabolome ameliorates the progression of non-alcoholic fatty liver disease. Clin. Transl. Med 11, e634 (2021).","journal-title":"Clin. Transl. Med"},{"key":"73166_CR10","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1080\/19490976.2020.1712984","volume":"11","author":"NY Lee","year":"2020","unstructured":"Lee, N. Y. et al. Lactobacillus and Pediococcus ameliorate progression of non-alcoholic fatty liver disease through modulation of the gut microbiome. Gut Microbes 11, 882\u2013899 (2020).","journal-title":"Gut Microbes"},{"key":"73166_CR11","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2025.2539448","volume":"17","author":"J Choi","year":"2025","unstructured":"Choi, J. et al. Phocaeicola dorei ameliorates progression of steatotic liver disease by regulating bile acid, lipid, inflammation and proliferation. Gut Microbes 17, 2539448 (2025).","journal-title":"Gut Microbes"},{"key":"73166_CR12","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1161\/CIRCULATIONAHA.118.033714","volume":"138","author":"N Yoshida","year":"2018","unstructured":"Yoshida, N. et al. Bacteroides vulgatus and Bacteroides dorei reduce gut microbial lipopolysaccharide production and inhibit atherosclerosis. Circulation 138, 2486\u20132498 (2018).","journal-title":"Circulation"},{"key":"73166_CR13","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.1080\/10408398.2020.1802695","volume":"61","author":"C Wang","year":"2021","unstructured":"Wang, C. et al. Roles of intestinal bacteroides in human health and diseases. Crit. Rev. Food Sci. Nutr. 61, 3518\u20133536 (2021).","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"73166_CR14","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1007\/s10753-021-01442-x","volume":"44","author":"Y Wang","year":"2021","unstructured":"Wang, Y. & Liu, Y. Neutrophil-induced liver injury and interactions between neutrophils and liver sinusoidal endothelial cells. Inflammation 44, 1246\u20131262 (2021).","journal-title":"Inflammation"},{"key":"73166_CR15","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/imr.12453","volume":"273","author":"MC Greenlee-Wacker","year":"2016","unstructured":"Greenlee-Wacker, M. C. Clearance of apoptotic neutrophils and resolution of inflammation. Immunol. Rev. 273, 357\u2013370 (2016).","journal-title":"Immunol. Rev."},{"key":"73166_CR16","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1002\/hep4.2057","volume":"6","author":"KH Kim","year":"2022","unstructured":"Kim, K. H., Cheng, N. & Lau, L. F. Cellular communication network factor 1-stimulated liver macrophage efferocytosis drives hepatic stellate cell activation and liver fibrosis. Hepatol. Commun. 6, 2798\u20132811 (2022).","journal-title":"Hepatol. Commun."},{"key":"73166_CR17","doi-asserted-by":"publisher","first-page":"4891","DOI":"10.4049\/jimmunol.1402164","volume":"194","author":"L Sun","year":"2015","unstructured":"Sun, L. et al. Ex vivo and in vitro effect of serum amyloid a in the induction of macrophage M2 markers and efferocytosis of apoptotic neutrophils. J. Immunol. 194, 4891\u20134900 (2015).","journal-title":"J. Immunol."},{"key":"73166_CR18","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1002\/hep4.2057","volume":"6","author":"K-H Kim","year":"2022","unstructured":"Kim, K.-H., Cheng, N. & Lau, L. F. Cellular communication network factor 1-stimulated liver macrophage efferocytosis drives hepatic stellate cell activation and liver fibrosis. Hepatol. Commun. 6, 2798\u20132811 (2022).","journal-title":"Hepatol. Commun."},{"key":"73166_CR19","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.chom.2019.03.007","volume":"25","author":"S Zhao","year":"2019","unstructured":"Zhao, S. et al. Adaptive evolution within gut microbiomes of healthy people. Cell Host Microbe 25, 656\u2013667. e658 (2019).","journal-title":"Cell Host Microbe"},{"key":"73166_CR20","doi-asserted-by":"publisher","first-page":"mBio 7","DOI":"10.1128\/mBio.01713-16","volume":"7","author":"J Vineis","year":"2016","unstructured":"Vineis, J. et al. Patient-Specific Bacteroides Genome Variants in Pouchitis. mBio 7, mBio 7 (2016).","journal-title":"mBio"},{"key":"73166_CR21","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1002\/hep.31672","volume":"73","author":"CJ Pirola","year":"2021","unstructured":"Pirola, C. J. & Sookoian, S. NAFLD and Cardiometabolic Risk Factors: The Liver Fibrosis Trajectory Through the Lens of Biological Interactions. Hepatology 73, 479\u2013482 (2021).","journal-title":"Hepatology"},{"key":"73166_CR22","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.jhep.2020.01.017","volume":"72","author":"JS Bajaj","year":"2020","unstructured":"Bajaj, J. S. & Khoruts, A. Microbiota changes and intestinal microbiota transplantation in liver diseases and cirrhosis. J. Hepatol. 72, 1003\u20131027 (2020).","journal-title":"J. Hepatol."},{"key":"73166_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.571847","volume":"11","author":"Q Liang","year":"2020","unstructured":"Liang, Q. et al. Gut microbiome contributes to liver fibrosis impact on T cell receptor immune repertoire. Front. Microbiol. 11, 571847 (2020).","journal-title":"Front. Microbiol."},{"key":"73166_CR24","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1038\/s41586-024-07372-6","volume":"629","author":"Y Miyamoto","year":"2024","unstructured":"Miyamoto, Y. et al. Periportal macrophages protect against commensal-driven liver inflammation. Nature 629, 901\u2013909 (2024).","journal-title":"Nature"},{"key":"73166_CR25","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/nri.2016.49","volume":"16","author":"S de Oliveira","year":"2016","unstructured":"de Oliveira, S., Rosowski, E. E. & Huttenlocher, A. Neutrophil migration in infection and wound repair: going forward in reverse. Nat. Rev. Immunol. 16, 378\u2013391 (2016).","journal-title":"Nat. Rev. Immunol."},{"key":"73166_CR26","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1053\/j.gastro.2004.10.005","volume":"128","author":"M Imamura","year":"2005","unstructured":"Imamura, M., Ogawa, T., Sasaguri, Y., Chayama, K. & Ueno, H. Suppression of macrophage infiltration inhibits activation of hepatic stellate cells and liver fibrogenesis in rats. Gastroenterology 128, 138\u2013146 (2005).","journal-title":"Gastroenterology"},{"key":"73166_CR27","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.jhep.2016.05.041","volume":"65","author":"D Ye","year":"2016","unstructured":"Ye, D. et al. Lipocalin-2 mediates non-alcoholic steatohepatitis by promoting neutrophil-macrophage crosstalk via the induction of CXCR2. J. Hepatol. 65, 988\u2013997 (2016).","journal-title":"J. Hepatol."},{"key":"73166_CR28","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1111\/liv.14940","volume":"41","author":"D Cheng","year":"2021","unstructured":"Cheng, D. et al. Hepatic macrophages: key players in the development and progression of liver fibrosis. Liver Int. 41, 2279\u20132294 (2021).","journal-title":"Liver Int."},{"key":"73166_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01163-8","volume":"21","author":"Z Liao","year":"2023","unstructured":"Liao, Z. et al. Myofiber directs macrophages IL-10-Vav1-Rac1 efferocytosis pathway in inflamed muscle following CTX myoinjury by activating the intrinsic TGF-beta signaling. Cell Commun. Signal 21, 168 (2023).","journal-title":"Cell Commun. Signal"},{"key":"73166_CR30","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1016\/j.bbadis.2016.06.009","volume":"1862","author":"O Moti\u00f1o","year":"2016","unstructured":"Moti\u00f1o, O. et al. Cyclooxygenase-2 expression in hepatocytes attenuates non-alcoholic steatohepatitis and liver fibrosis in mice. Biochim. et. Biophys. Acta (BBA) Mol. Basis Dis. 1862, 1710\u20131723 (2016).","journal-title":"Biochim. et. Biophys. Acta (BBA) Mol. Basis Dis."},{"key":"73166_CR31","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41577-019-0240-6","volume":"20","author":"AC Doran","year":"2020","unstructured":"Doran, A. C., Yurdagul, A. & Tabas, I. Efferocytosis in health and disease. Nat. Rev. Immunol. 20, 254\u2013267 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"73166_CR32","doi-asserted-by":"publisher","first-page":"585285","DOI":"10.3389\/fendo.2020.585285","volume":"11","author":"L Wang","year":"2021","unstructured":"Wang, L., Li, H., Tang, Y. & Yao, P. Potential mechanisms and effects of efferocytosis in atherosclerosis. Front. Endocrinol. 11, 585285 (2021).","journal-title":"Front. Endocrinol."},{"key":"73166_CR33","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.jcmgh.2022.01.002","volume":"13","author":"D Meriwether","year":"2022","unstructured":"Meriwether, D. et al. Macrophage COX2 mediates efferocytosis, resolution reprogramming, and intestinal epithelial repair. Cell. Mol. Gastroenterol. Hepatol. 13, 1095\u20131120 (2022).","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"73166_CR34","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3389\/fphys.2018.00113","volume":"9","author":"C Rosales","year":"2018","unstructured":"Rosales, C. Neutrophil: A cell with many roles in inflammation or several cell types? Front. Physiol. 9, 113 (2018).","journal-title":"Front. Physiol."},{"key":"73166_CR35","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1136\/thoraxjnl-2016-208879","volume":"71","author":"AE Williams","year":"2016","unstructured":"Williams, A. E. & Chambers, R. C. Neutrophils and tissue damage: Is hypoxia the key to excessive degranulation?. Thorax 71, 977\u2013978 (2016).","journal-title":"Thorax"},{"key":"73166_CR36","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jhep.2020.02.025","volume":"73","author":"Q Liu","year":"2020","unstructured":"Liu, Q. et al. Inhibition of PU.1 ameliorates metabolic dysfunction and non-alcoholic steatohepatitis. J. Hepatol. 73, 361\u2013370 (2020).","journal-title":"J. Hepatol."},{"key":"73166_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100960","volume":"6","author":"H Shi","year":"2024","unstructured":"Shi, H., Moore, M. P., Wang, X. & Tabas, I. Efferocytosis in liver disease. JHEP Rep. 6, 100960 (2024).","journal-title":"JHEP Rep."},{"key":"73166_CR38","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ajpath.2012.09.007","volume":"182","author":"S Bhattacharyya","year":"2013","unstructured":"Bhattacharyya, S. et al. Toll-like receptor 4 signaling augments transforming growth factor-\u03b2 responses: a novel mechanism for maintaining and amplifying fibrosis in scleroderma. Am. J. Pathol. 182, 192\u2013205 (2013).","journal-title":"Am. J. Pathol."},{"key":"73166_CR39","doi-asserted-by":"crossref","unstructured":"Theall, B. & Alcaide, P. The heart under pressure: immune cells in fibrotic remodeling. Curr. Opin. Physiol. 25, 100484 (2022).","DOI":"10.1016\/j.cophys.2022.100484"},{"key":"73166_CR40","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3350\/cmh.2023.0437","volume":"30","author":"S Fukunaga","year":"2023","unstructured":"Fukunaga, S., Mukasa, M., Nakano, D., Tsutsumi, T. & Kawaguchi, T. Changing from NAFLD to MASLD: Similar cumulative incidence of reflux esophagitis between NAFLD and MASLD. Clin. Mol. Hepatol. 30, 121 (2023).","journal-title":"Clin. Mol. Hepatol."},{"key":"73166_CR41","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella, M. E. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 78, 1966\u20131986 (2023).","journal-title":"Hepatology"},{"key":"73166_CR42","doi-asserted-by":"publisher","first-page":"845","DOI":"10.3350\/cmh.2024.0349","volume":"30","author":"SP Sharma","year":"2024","unstructured":"Sharma, S. P. et al. Gut microbiome and metabolome signatures in liver cirrhosis-related complications. Clin. Mol. Hepatol. 30, 845 (2024).","journal-title":"Clin. Mol. Hepatol."},{"key":"73166_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2180-10-316","volume":"10","author":"RC Anderson","year":"2010","unstructured":"Anderson, R. C. et al. Lactobacillus plantarum MB452 enhances the function of the intestinal barrier by increasing the expression levels of genes involved in tight junction formation. BMC Microbiol. 10, 316 (2010).","journal-title":"BMC Microbiol."},{"key":"73166_CR44","doi-asserted-by":"publisher","first-page":"6025","DOI":"10.1002\/jcp.30288","volume":"236","author":"J Xue","year":"2021","unstructured":"Xue, J. et al. miR-21-regulated M2 polarization of macrophage is involved in arsenicosis-induced hepatic fibrosis through the activation of hepatic stellate cells. J. Cell. Physiol. 236, 6025\u20136041 (2021).","journal-title":"J. Cell. Physiol."},{"key":"73166_CR45","doi-asserted-by":"crossref","unstructured":"Millius, A. & Weiner, O. D. in Live Cell Imaging: Methods and Protocols, 147\u2013158 (Springer, 2009).","DOI":"10.1007\/978-1-60761-404-3_9"},{"key":"73166_CR46","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jcmgh.2018.01.003","volume":"5","author":"Z Zhou","year":"2018","unstructured":"Zhou, Z. et al. Neutrophil\u2013hepatic stellate cell interactions promote fibrosis in experimental steatohepatitis. Cell. Mol. Gastroenterol. Hepatol. 5, 399\u2013413 (2018).","journal-title":"Cell. Mol. Gastroenterol. Hepatol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73166-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73166-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73166-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T02:03:06Z","timestamp":1784253786000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73166-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,17]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["73166"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-73166-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,17]]},"assertion":[{"value":"6 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"6516"}}